Halozyme Therapeutics Bolsa (NASDAQ: HALO)

Últimas noticias sobre Halozyme Therapeutics (NASDAQ:HALO) Bolsa

Halozyme Therapeutics

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

BGNE

HALO

2 acciones del sector de la salud muestran un RSI alto, lo que podría ser una advertencia clave para los inversores centrados en el momentum.

2 acciones de atención médica que podrían desplomarse en agosto

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics Inc

HALO COLLECTIVE INC by HALO COLLECTIVE INC.

Halo Collective Inc

In the last three months, 11 analysts have published ratings on Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $64.55, a high estimate of $73.00, and a low estimate of $52.00. Marking an increase of 0.44%, the current average surpasses the previous average price target of $64.27. 
<img src="https://www.benzinga.com/files/images/story/2025/1736794851_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Halozyme Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$57.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$53.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$73.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Halozyme Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Halozyme Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Halozyme Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Halozyme Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HALO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Halozyme Therapeutics analyst ratings.</a>
<h2>Delving into Halozyme Therapeutics's Background</h2>
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
<h3>Halozyme Therapeutics's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Halozyme Therapeutics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 34.28%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Halozyme Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 47.23% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Halozyme Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 36.92% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 6.7%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.32, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For Halozyme Therapeutics's Future

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Equal-Weight and lowers the price target from $62 to $57.

Price Target

Wells Fargo Maintains Equal-Weight on Halozyme Therapeutics, Lowers Price Target to $57

Piper Sandler analyst Joseph Catanzaro maintains Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Neutral and raises the price target from $52 to $53.

Piper Sandler Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $53

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and raises the price target from $68 to $70.

HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $70

WIIM

Halozyme Therapeutics shares are trading higher after the company reported preliminary financial results and raised its FY25 guidance.

Guidance

Halozyme Raises 2025 Financial Guidance Ranges For Total Revenue To $1.150B - $1.225B From $1.095B to $1.170B (Vs. Cons. Of $1.156B), Adj. EPS To $4.95 - $5.35 From $4.45 to $4.85 (Vs. Cons. $4.83)

Halozyme Reports Preliminary Results, Reiterated Full Year 2024 Financial Guidance

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and maintains $68 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $68 Price Target

"We are pleased that VYVDURA, with our innovative ENHANZE drug delivery technology, is now approved for two indications in Japan, enabling greater flexibility and optionality for generalized myasthenia gravis and CIDP patients," said Dr. Helen Torley, president and chief executive officer of Halozyme. "We look forward to VYVDURA being a new treatment option for an even broader number of patients in Japan."

Halozyme Says argenx's VYDURA With ENHANZE Granted Regulatory Approval In Japan For Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) (Halozyme) today announced that Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval for Opdivo Qvantig&#x2122; (nivolumab and hyaluronidase-nvhy) co-formulated with Halozyme's ENHANZE&#xAE; drug delivery technology for subcutaneous use in most previously approved adult, solid tumor intravenous (IV) Opdivo&#xAE; indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy&#xAE; (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. Opdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor.&nbsp;
The subcutaneous administration of Opdivo Qvantig is faster, with a three- to five-minute administration time compared to 30 minutes for IV Opdivo.&#x2A;&nbsp; Subcutaneous administration may offer flexibility to receive treatment where it is best for patients and their providers, may reduce steps required for preparation and time needed for administration.

Government

Regulations

Halozyme and Bristol Myers Squibb Secure FDA Nod for Opdivo Qvantig

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $65.44, a high estimate of $73.00, and a low estimate of $52.00. Marking an increase of 1.55%, the current average surpasses the previous average price target of $64.44. 
<img src="https://www.benzinga.com/files/images/story/2024/1734523210_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Halozyme Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$73.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Halozyme Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Halozyme Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Halozyme Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Halozyme Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HALO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Halozyme Therapeutics analyst ratings.</a>
<h2>Delving into Halozyme Therapeutics's Background</h2>
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
<h3>Key Indicators: Halozyme Therapeutics's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Halozyme Therapeutics showcased positive performance, achieving a revenue growth rate of 34.28% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Halozyme Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 47.23% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 36.92%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Halozyme Therapeutics's ROA excels beyond industry benchmarks, reaching 6.7%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 3.32, Halozyme Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

9 Analysts Have This To Say About Halozyme Therapeutics

Halozyme Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NYSE">HALO</a>) short percent of float has fallen 18.07% since its last report. The company recently reported that it has 8.57 million shares sold short, which is 9.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Halozyme Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733942717_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Halozyme Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Halozyme Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Halozyme Therapeutics's peer group average for short interest as a percentage of float is 12.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

(HALO) - Analyzing Halozyme Therapeutics's Short Interest

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) for 11 euro ($11.44) per share in cash, implying a fully <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42137175/halozyme-withdraws-proposal-to-acquire-evotec-following-evotecs-unwillingness-to-engage-in-discuss" rel="noreferrer noopener">diluted equity value of 2.0 billion euro.</a>
This move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said.
In addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling continued growth.
The company expects revenue between $970 million and $1.02 billion ($1.003 billion) and an adjusted EBITDA range of $595 million to $625 million, reflecting significant double-digit growth.
Halozyme is confident in its ability to execute its strategy, with the goal of achieving ten approved products with ENHANZE by 2025 and $1 billion in royalty revenue by 2027.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/24/11/42141413/us-business-activity-soars-to-31-month-highs-in-november-small-caps-rally-dow-tops-44000" rel="noreferrer noopener">US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000</a>
Helen Torley, CEO of Halozyme, explained that although the merger would have created a leading global pharma services company, Evotec was not open to further discussions.
Halozyme&#8217;s efforts to engage with Evotec&#8217;s leadership, including multiple requests for meetings, were unsuccessful, leading to the decision to withdraw the offer.
&#8220;A company spokesperson has publicly commented that its goal is to remain an independent company,&#8221; said Helen Torley,&nbsp;president and chief executive officer of Halozyme regarding Evotec, adding that &#8220;our multiple requests to meet were not accepted&#8221;.
&#8220;Evotec has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec for EUR11.00 per share in cash,&#8221; Evotec <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac42141986/comment-on-withdrawn-non-binding-offer" rel="noreferrer noopener">said in a response.</a>
Price Action: HALO shares are trading higher by 6.21% to $48.54 at last check Friday, while EVO shares are down 18.8% to $4.345.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42137929/2025-us-economy-outlook-cloudier-than-normal-jpmorgan-says-boom-bust-scenarios" target="_blank" rel="noreferrer noopener">2025 US Economy Outlook&#8217; Cloudier Than Normal,&#8217; JPMorgan Says: Boom, Bust Scenarios</a></li>
</ul>

Equities

Movers

General

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Halozyme Therapeutics shares are trading higher after the company announced it withdrew plans to acquire Evotec.

Halozyme Withdraws €2B Proposal To Acquire Evotec After Evotec Declines Engagement, Citing Commitment To Independence; Halozyme Reaffirms 2024 Guidance And Strategic Growth Targets

In the last three months, 10 analysts have published ratings on Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Halozyme Therapeutics, revealing an average target of $64.0, a high estimate of $73.00, and a low estimate of $52.00. This current average reflects an increase of 2.24% from the previous average price target of $62.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1732118464_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Halozyme Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$73.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Halozyme Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Halozyme Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Halozyme Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Halozyme Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HALO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Halozyme Therapeutics analyst ratings.</a>
<h2>Get to Know Halozyme Therapeutics Better</h2>
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
<h3>Unraveling the Financial Story of Halozyme Therapeutics</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Halozyme Therapeutics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 34.28%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Halozyme Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 47.23% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Halozyme Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 36.92%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Halozyme Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.7%, the company showcases efficient use of assets and strong financial health.
Debt Management: Halozyme Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 3.32. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views

Halozyme Therapeutics shares are trading lower after the company announced a proposal to combine with Evotec.

Analysts fell to the sidelines weighing in on Halozyme (HALO – Research Report) and SAGE Therapeutics (SAGE – Research Report) with neutral ratings...

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and SAGE Therapeutics (SAGE)

TD Cowen analyst Brendan Smith reiterated a Buy rating on Halozyme (HALO – Research Report) today and set a price target of $77.00. Brendan Smith h...

Halozyme: Undervalued Growth Potential Amidst Strong Core Business and Future Opportunities

Corporate candidates to announce accelerate share buybacks: Trivariate

Leerink Partners analyst David Risinger maintained a Hold rating on Halozyme (HALO – Research Report) on January 12 and set a price target of $58.0...

Balanced Outlook on Halozyme Amid Litigation and Strategic Uncertainty Warrants Hold Rating

The biotech market offers great investment potential due to innovative advancements in genetic profiling, biologics, CRISPR technology, and rare disease treatments driving strong demand and growth. Therefore, investing in strong biotech stocks like Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR) could be wise. Read on... The biotech sector is revolutionizing healthcare with tailored treatments driven by affordable genetic profiling, enhancing efficacy while reducing side effects. This innovation fuels robust demand and strong growth potential for leaders in the field.
Therefore, as niche biotech pioneers redefine innovation, investors may consider top stocks like Halozyme Therapeutics, Inc. (<a href="https://stocknews.com/stock/HALO/">HALO</a>), BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>),  and United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>), for solid gains.
This niche sector thrives as biologics address complex diseases, with rising biosimilar approvals enhancing accessibility and expanding market opportunities. Meanwhile, emerging markets are driving growth through increased biotech investments, intensifying competition. The global biotechnology market is projected to reach $546 billion by 2025, reflecting a <a href="https://www.prnewswire.com/news-releases/global-biotechnology-market-outlook-2025-driving-growth-at-13-0-cagr--marketsandmarkets-302346776.html">CAGR of 13%</a>, despite economic uncertainties.
Notably, recent innovations in CRISPR technology enable precise DNA modifications, opening new avenues in medicine and agriculture. Biotech companies pioneering these technologies hold transformative potential. Additionally, the rare disease segment stands out for its high profitability, supported by exclusivity and incentives, making it an attractive niche for strategic investments.
Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: Halozyme Therapeutics, Inc. (<a href="https://stocknews.com/stock/HALO/">HALO</a>)
HALO is a biopharma technology platform company that researches, develops, and commercializes proprietary enzymes and devices internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20), which enables the delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
On December 30, 2024, HALO announced that Takeda received Japanese regulatory approval for HYQVIA, the first subcutaneous immunoglobulin therapy with reduced dosing frequency for patients with primary or secondary immunodeficiency. This therapy utilizes HALO's ENHANZE technology to improve absorption and administration flexibility.
On the same date, HALO announced FDA approval of Opdivo Qvantig, the first subcutaneously administered PD-1 inhibitor, co-formulated with its ENHANZE technology. This new formulation offers faster administration and comparable efficacy and safety to IV Opdivo, enhancing treatment flexibility for patients with solid tumors.
In terms of the trailing-12-month asset turnover ratio, HALO's 0.47x is 13.7% higher than the 0.42x industry average. Similarly, its 58.37% trailing-12-month <a href="https://www.investopedia.com/terms/e/ebitda-margin.asp">EBITDA margin</a> is 888.7% higher than the 5.90% industry average. Its 50.35% trailing-12-month EBIT margin is substantially higher than the 2.69% industry average.
HALO's total revenues for the third quarter ended September 30, 2024, rose 34.3% year-over-year to $290.08 million. Its operating income came in at $163.20 million, up 84.9% over the year-ago quarter.
For the same quarter, the company's net income and EPS grew 67.4% and 72.1% from the year-ago values to $137.01 million, or $1.05 per share, respectively. In addition, its adjusted EBITDA rose 59.8% year-over-year to $183.56 million.
Analysts expect HALO's revenue for the quarter ended December 31, 2024, to increase 24.2% year-over-year to $285.74 million. Its EPS for the same quarter is expected to grow 41.3% year-over-year to $1.16. The company surpassed the Street EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 56.4%, closing the last trading session at $53.83.
HALO's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its positive prospects. It has an overall B rating, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.
HALO has a B grade for Growth, Value, and Quality. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #30 out of 334 stocks. <a href="https://stocknews.com/stock/HALO/">Click here</a> for the additional POWR Ratings of HALO (Momentum, Stability, and Sentiment).
Stock #2: BioMarin Pharmaceutical Inc. (<a href="https://stocknews.com/stock/BMRN/">BMRN</a>)
BMRN develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, Naglazyme, and Kuvan.
In terms of the trailing-12-month levered FCF margin, BMRN's 5.26% is 140.1% higher than the 2.19% industry average. Its 15.48% trailing-12-month EBITDA margin is 162.2% higher than the 5.90% industry average. Also, its 3.44% trailing-12-month Capex / Sales is 10.7% higher than the 3.11% industry average.
For the fiscal third quarter, which ended on September 30, 2024, BMRN's total revenues increased by 28.3% year-over-year to $745.74 million. Its non-GAAP income and non-GAAP EPS rose 100% and 97.8% over the prior-year quarter, reaching $178 million and $0.91, respectively. Moreover, BMRN's non-GAAP income from operations was $207 million, up 120.2% year-over-year.
For the quarter ended December 31, 2024, BMRN's EPS and revenue are expected to increase 45.1% and 10.1% year-over-year to $0.71 and $711.32 million, respectively. BMRN surpassed the consensus EPS estimates in each of the trailing four quarters. Over the past month, the stock has declined 3.3% to close the last trading session at $63.81.
It's no surprise that BMRN has an overall rating of B, which translates to a Buy in our proprietary rating system.
It is ranked #10 in the same industry. It has an A grade for Growth and a B for Value and Sentiment. <a href="https://stocknews.com/stock/BMRN/">Click here</a> to see BMRN's Momentum, Stability, and Quality ratings.
Stock #1: United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>)
UTHR is a biotechnology company that engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally.
On December 17, 2024, UTHR announced the world's first successful transplant of a UKidney, a genetically engineered pig kidney, into a living human. This milestone builds on prior xenotransplants and advances the company's mission to address organ shortages through innovative solutions like xenotransplantation and other organ alternatives.
In terms of the trailing-12-month gross profit margin, UTHR's 88.94% is 52.4% higher than the 58.37% industry average. Likewise, its 51.23% trailing-12-month EBITDA margin is 767.8% higher than the 5.90% industry average. Its 48.82% trailing-12-month EBIT margin is substantially higher than the 2.69% industry average.
UTHR's total revenues for the third quarter, which ended September 30, 2024, increased 22.9% year-over-year to $748.90 million. Its operating income rose 4.9% from the year-ago value to $343.10 million. For the same quarter, the company's net income came in at $309.10 million, or $6.39 per common share, representing an increase of 15.5% and 18.8% over the prior-year quarter, respectively.
Street expects UTHR's EPS and revenue for the quarter ended December 31, 2024, is expected to increase 46.4% and 20.4% year-over-year to $6.38 and $739.92 million, respectively. UTHR's stock has gained 66.5% over the past year to close the last trading session at $364.70.
UTHR's positive outlook is reflected in its POWR Ratings. It has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
It has an A grade for Value and a B for Quality. Within the Biotech industry, it is ranked #8. Beyond what we stated above, we also have given UTHR grades for Growth, Momentum, Stability, and Sentiment. Get all the UTHR ratings <a href="https://stocknews.com/stock/UTHR/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
UTHR shares were trading at $364.87 per share on Wednesday morning, up $0.17 (+0.05%). Year-to-date, UTHR has gained 3.41%, versus a 0.70% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/uthr-bmrn-halo-3-niche-biotech-stocks-redefining-innovation/>3 Niche Biotech Stocks Redefining Innovation</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Niche Biotech Stocks Redefining Innovation

ATGE

AZEK

AZTA

BMRN

CACI

CDNS

GWRE

KLAC

SAGE

SNPS

UTHR

WING

Earnings

Press Releases

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

Halozyme to Present at Upcoming Investor Conferences

Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications

Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Comments

Halozyme Therapeutics

Noticias

Últimas noticias sobre Halozyme Therapeutics (NASDAQ:HALO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL